The Potential Role of Epigenetic Mechanisms in the Development of Retinitis Pigmentosa and Related Photoreceptor Dystrophies

Overview

Journal Front Genet

Date 2022 Apr 1

PMID 35360866

Authors

Galina Dvoriantchikova

Karin Rose Lypka

Dmitry Ivanov

Affiliations

Soon will be listed here.

Abstract

Retinitis pigmentosa and related photoreceptor dystrophies (RPRPD) are rare retinal diseases caused by hereditary gene mutations resulting in photoreceptor death, followed by vision loss. While numerous genes involved in these diseases have been identified, many cases have still not been associated with any gene, indicating that new mechanisms may be involved in the pathogenesis of these photoreceptor dystrophies. Many genes associated with RPRPD regulate photoreceptor specification and maturation in the developing retina. Since retinal development begins with a population of equivalent, proliferating retinal progenitor cells (RPCs) having a specific "competence" in generating all types of retinal neurons, including cone and rod photoreceptors, we tested the epigenetic changes in promoters of genes required for photoreceptor development and genes associated with RPRPD during RPC differentiation into cone and rod photoreceptors. We found that promoters of many of these genes are epigenetically repressed in RPCs but have no epigenetic restrictions in photoreceptors. Our findings also suggest that DNA methylation as an epigenetic mark, and DNA demethylation as a process, are more important than other epigenetic marks or mechanisms in the pathogenesis of these diseases. Most notably, irregularities in the DNA demethylation process during the RPC-to-photoreceptor transition may significantly contribute to retinitis pigmentosa (RP) pathogenesis since genes with hypermethylated promoters in RPCs account for at least 40% of autosomal recessive RP cases and at least 30% of autosomal dominant RP cases. Thus, we proposed an epigenetic model according to which unsuccessful demethylation of regulatory sequences (e.g., promoters, enhancers) of genes required for photoreceptor development, maturation, and function during the RPC-to-photoreceptor transition may reduce or even eliminate their activity, leading to RPRPD without any inheritable mutations in these genes.

Citing Articles

Active DNA demethylation is upstream of rod-photoreceptor fate determination and required for retinal development.

Hernandez-Nunez I, Urman A, Zhang X, Jacobs W, Hoffman C, Rebba S bioRxiv. 2025; .

PMID: 39975078 PMC: 11838574. DOI: 10.1101/2025.02.03.636318.

tet2 and tet3 regulate cell fate specification and differentiation events during retinal development.

Heilman S, Schriever H, Kostka D, Koenig K, Gross J bioRxiv. 2024; .

PMID: 39713311 PMC: 11661121. DOI: 10.1101/2024.12.06.627071.

Using Small Molecules to Reprogram RPE Cells in Regenerative Medicine for Degenerative Eye Disease.

Rzhanova L, Alpeeva E, Aleksandrova M Cells. 2024; 13(23).

PMID: 39682681 PMC: 11640686. DOI: 10.3390/cells13231931.

Traversing the epigenetic landscape: DNA methylation from retina to brain in development and disease.

Xu C, Fu X, Qin H, Yao K Front Cell Neurosci. 2024; 18:1499719.

PMID: 39678047 PMC: 11637887. DOI: 10.3389/fncel.2024.1499719.

Evaluating therapeutic potential of NR2E3 doses in the rd7 mouse model of retinal degeneration.

McNamee S, Akula M, Love Z, Nasraty N, Nystuen K, Singh P Sci Rep. 2024; 14(1):16490.

PMID: 39019967 PMC: 11254931. DOI: 10.1038/s41598-024-67095-6.

References

Yao B, Jin P . Unlocking epigenetic codes in neurogenesis. Genes Dev. 2014; 28(12):1253-71. PMC: 4066397. DOI: 10.1101/gad.241547.114. View

Miao Z, He Y, Xin N, Sun M, Chen L, Lin L . Altering 5-hydroxymethylcytosine modification impacts ischemic brain injury. Hum Mol Genet. 2015; 24(20):5855-66. PMC: 4581609. DOI: 10.1093/hmg/ddv307. View

Herceg Z, Hainaut P . Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis. Mol Oncol. 2009; 1(1):26-41. PMC: 5543860. DOI: 10.1016/j.molonc.2007.01.004. View

Fattal-Valevski A, Eliyahu H, Fraenkel N, Elmaliach G, Hausman-Kedem M, Shaag A . Homozygous mutation, p.Pro304His, in IDH3A, encoding isocitrate dehydrogenase subunit is associated with severe encephalopathy in infancy. Neurogenetics. 2017; 18(1):57-61. DOI: 10.1007/s10048-016-0507-z. View

Vissers M, Kuiper C, Dachs G . Regulation of the 2-oxoglutarate-dependent dioxygenases and implications for cancer. Biochem Soc Trans. 2014; 42(4):945-51. DOI: 10.1042/BST20140118. View

Pierrache L, Kimchi A, Ratnapriya R, Roberts L, Astuti G, Obolensky A . Whole-Exome Sequencing Identifies Biallelic IDH3A Variants as a Cause of Retinitis Pigmentosa Accompanied by Pseudocoloboma. Ophthalmology. 2017; 124(7):992-1003. PMC: 5868413. DOI: 10.1016/j.ophtha.2017.03.010. View

Lopez-Moyado I, Tsagaratou A, Yuita H, Seo H, Delatte B, Heinz S . Paradoxical association of TET loss of function with genome-wide DNA hypomethylation. Proc Natl Acad Sci U S A. 2019; 116(34):16933-16942. PMC: 6708373. DOI: 10.1073/pnas.1903059116. View

Gill J, Georgiou M, Kalitzeos A, Moore A, Michaelides M . Progressive cone and cone-rod dystrophies: clinical features, molecular genetics and prospects for therapy. Br J Ophthalmol. 2019; . PMC: 6709772. DOI: 10.1136/bjophthalmol-2018-313278. View

Kaas G, Zhong C, Eason D, Ross D, Vachhani R, Ming G . TET1 controls CNS 5-methylcytosine hydroxylation, active DNA demethylation, gene transcription, and memory formation. Neuron. 2013; 79(6):1086-93. PMC: 3816951. DOI: 10.1016/j.neuron.2013.08.032. View

10.

Burger L, Gaidatzis D, Schubeler D, Stadler M . Identification of active regulatory regions from DNA methylation data. Nucleic Acids Res. 2013; 41(16):e155. PMC: 3763559. DOI: 10.1093/nar/gkt599. View

11.

Wiehle L, Raddatz G, Musch T, Dawlaty M, Jaenisch R, Lyko F . Tet1 and Tet2 Protect DNA Methylation Canyons against Hypermethylation. Mol Cell Biol. 2015; 36(3):452-61. PMC: 4719427. DOI: 10.1128/MCB.00587-15. View

12.

Bochtler M, Kolano A, Xu G . DNA demethylation pathways: Additional players and regulators. Bioessays. 2016; 39(1):1-13. DOI: 10.1002/bies.201600178. View

13.

Charlton J, Jung E, Mattei A, Bailly N, Liao J, Martin E . TETs compete with DNMT3 activity in pluripotent cells at thousands of methylated somatic enhancers. Nat Genet. 2020; 52(8):819-827. PMC: 7415576. DOI: 10.1038/s41588-020-0639-9. View

14.

Guo J, Ma D, Mo H, Ball M, Jang M, Bonaguidi M . Neuronal activity modifies the DNA methylation landscape in the adult brain. Nat Neurosci. 2011; 14(10):1345-51. PMC: 3183401. DOI: 10.1038/nn.2900. View

15.

Xu Y, Xu C, Kato A, Tempel W, Abreu J, Bian C . Tet3 CXXC domain and dioxygenase activity cooperatively regulate key genes for Xenopus eye and neural development. Cell. 2012; 151(6):1200-13. PMC: 3705565. DOI: 10.1016/j.cell.2012.11.014. View

16.

Zeitz C, Robson A, Audo I . Congenital stationary night blindness: an analysis and update of genotype-phenotype correlations and pathogenic mechanisms. Prog Retin Eye Res. 2014; 45:58-110. DOI: 10.1016/j.preteyeres.2014.09.001. View

17.

Li X, Yue X, Pastor W, Lin L, Georges R, Chavez L . Tet proteins influence the balance between neuroectodermal and mesodermal fate choice by inhibiting Wnt signaling. Proc Natl Acad Sci U S A. 2016; 113(51):E8267-E8276. PMC: 5187696. DOI: 10.1073/pnas.1617802113. View

18.

Dvoriantchikova G, Seemungal R, Ivanov D . DNA Methylation Dynamics During the Differentiation of Retinal Progenitor Cells Into Retinal Neurons Reveal a Role for the DNA Demethylation Pathway. Front Mol Neurosci. 2019; 12:182. PMC: 6667802. DOI: 10.3389/fnmol.2019.00182. View

19.

Balmain A . Cancer genetics: from Boveri and Mendel to microarrays. Nat Rev Cancer. 2002; 1(1):77-82. DOI: 10.1038/35094086. View

20.

Feinberg A, Tycko B . The history of cancer epigenetics. Nat Rev Cancer. 2004; 4(2):143-53. DOI: 10.1038/nrc1279. View